1) **Project Objective:** The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) is charged with addressing the potential threat to the armed services posed by a wide range of bacterial, viral and toxin agents. This objective of this project is to identify current and developing technologies that can rapidly and accurately identify immunogenic regions of antigen in new and emerging pathogens. This effort will support JSTO CBM vaccine programs by developing technologies to rapidly and accurately identify antigenic components in emerging pathogens that elicit significant and persistent protective immunity, and which can be incorporated into current vaccine platform.

2) **Performance Objectives (required results)**

    a. **Project Objectives:** JSTO is seeking proposals for the development of technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID) for vaccine development. The EID pathogens include, but are not limited to, viral, bacterial and pathogens, as well as synthetic and naturally derived toxins. These technologies would be expected to rapidly assess in silico (nucleic acid sequence) data from novel pathogens with epidemic or pandemic potential and identify antigens or specific epitopes that would successfully elicit substantial and sustained protective immunity. The proposed technology should provide sufficient data for the immediate inclusion of the antigen in an existing multiplex platform to optimize vaccine formulation and delivery.

    b. **Regulatory Objectives:** The vaccine antigen discovery product is expected to be compatible with multiple different vaccine formats. Successful candidates may be forwarded for advanced development in pre-INDs and eventually FDA clinical trials.

    c. **Project Management Objectives:** The project will be managed by a Government IPT including a Science and Technology Program Manager (STM), Program Management Office (PMO) and Subject Matter Expert (SME) support. The offeror will be expected to participate in monthly progress meetings as well as quarterly and annual programmatic, milestone and financial reports.

    d. Logistics Objectives: NA

3) **Performance Requirements: NA**

Operational constraints/Limitations/Restrictions: NA

2.1.3 PERIOD AND PLACE OF PERFORMANCE:

The anticipated Period of Performance for this effort is up to five (5) years from date of award. Specific dates to be negotiated during SOW development. It is anticipated that the primary place of performance will be the Agreement Holders' facilities or at a suitable subcontractor, however this aspect can be negotiated as part of each Offerors' submission.

2.1.4 DELIVERABLES:

2.1.4.1 DATA DELIVERABLE(S): Data deliverables include meeting minutes, financial reports, technical progress reports, annual reports, GFP inventory, patents and invention reports, regulatory documentation and technical data packages, forecasts, WBS, IMS, copies of FDA submissions (IND, BLA, eIND, etc) FDA correspondence, ORTA correspondence, Regulatory Strategy, TPP, and any other data necessary to document the product development.

Note: Technical data deliverables described herein shall be delivered to the Government with Government Purpose Rights.

2.1.4.2 PROTOTYPE DELIVERABLE(S): The Agreement Holder will deliver technologies that can accelerate the identification and immune profile of novel antigens. The quantity to be delivered should be limited to only that needed to prove technical or manufacturing feasibility or evaluate military utility.

2.1.5 SPECIAL REQUIREMENTS:

2.1.5.1 Export Control

2.1.5.2 Security and Classified Data: All information/data generated under this agreement will be designated as non-classified.

2.1.5.3 Acceptance of Deliverables: The Government will provide acceptance of all data deliverables within 30 days of delivery. The Government will provide acceptance of all prototype deliverables within 60 days of delivery**.**

2.1.5.4 Travel: The offeror will travel for Government purposes, including annual project meetings with DTRA and travel to project-relevant conferences. This will include two annual trips within the continental United States (CONUS) but may include non-directed travel the offeror thinks are necessary for the effort.

2.1.6 GOVERNMENT FURNISHED PROPERTY/SERVICE: NA

2.1.7 FUNDING CONFIDENCE LEVEL and PROJECT AWARD MONTH or FY QUARTER:

CL-3 Funding Availability is Unknown at this time.

This effort is anticipated for award: April FY2025

2.1.8 FOLLOW-ON PRODUCTION: This prototype project will be awarded after a competitive solicitation, evaluation and award process. As such, in accordance with 10 U.S.C. 4022 and upon a determination that the prototype project for this transaction has been successfully completed, or at the accomplishment of particularly favorable or unexpected results that would justify transitioning to production, any competitively awarded prototype OTA as a result of this RPP may result in the award of a follow-on production contract or transaction without the use of competitive procedures. A follow-on production effort may include the delivery of up to 2 Prototypes annually over a 1 fiscal year period.

2.1.9 AGREEMENTS OFFICER REPRESENTATIVE (AOR):

Name: Robert P. Webb, Ph.D.
Telephone: 571-616-3591
E-mail: robert.p.webb6.civ@mail.mil
Office Symbol: DTRA CBM

2.1.9.1 ALTERNATE AOR:

Name: Mary Zoepfl, Ph.D.
Telephone: 571-616-6373
E-mail: mary.e.zoepfl.civ@mail.mil
Office Symbol: DTRA CBM

2.1.9.2 Requiring Activity:

DTRA Joint Science and Technology Office Chem-Bio Medical (CBM)